ofloxacin brands

68 registered brands containing ofloxacin in Kenya.

Ofloxacin

PubChem CID 4583

Molecular formula: C18H20FN3O4

Ofloxacin acts on DNA gyrase and toposiomerase IV, enzymes which, like human topoisomerase, prevents the excessive supercoiling of DNA during replication or transcription. By inhibiting their function, the drug thereby inhibits normal cell division. Quinolone(s) (QNs) is widely used in infection therapy due to its good antimicrobial characteristics. However, QNs-induced arthropathy of immature animals has led to restrictions on the therapeutic use of these antimicrobial agents. The exact mechanism(s) of QNs-induced chondrotoxicity remain unknown. In the present study, .../the authors/ investigated the possible mechanism of ofloxacin (one typical QNs)-induced injuries of chondrocytes. Juvenile rabbit joint chondrocytes cultured in alginate microspheres were incubated with ofloxacin at concentrations of 0, 2, 5, 10, 20, and 40 microg/mL for up to 96 hr. Concentration of 10 microg/mL ofloxacin induced apoptosis of chondrocyte with visible apoptotic signs, including degradation of poly(ADP-ribose) polymerase, caspase-3 activation, and DNA ladder formation. Furthermore, extracellular signal-regulated kinase 1/2 (phospho-ERK1/2) and growth factor receptor-bound protein 2 (Grb2) were significantly reduced, and similar changes were also observed in the beta(1)-integrin receptor as assessed by immunoblotting. However, the mRNA level of beta(1)-integrin obtained from reverse transcription-polymerase chain reaction remained unchanged. Results of beta(1)-integrin immunoprecipitation have also shown that beta(1)-integrin did not interact with activated intracellular signaling proteins. In addition, ofloxacin did not induce apoptosis and decrease beta(1)-integrin expression in chondrocytes supplemented with Mg(2+), and the ofloxacin-induced apoptosis was caspase-8-dependent, inhibition of which did not affect the expression mode of phospho-ERK1/2 and beta(1)-integrin. Our results demonstrate that ofloxacin affects beta(1)-integrin receptor functions and the ERK mitogen-activated protein kinase signaling pathway, causing caspase-8-dependent apoptosis after exposure of 48 hr. Quinolones are widely used in infection therapy due to their good antimicrobial characteristics. However, there potential joint chondrotoxicity on immature animals has stood in the way of the therapeutic application of these agents, the exact mechanism of which is still unclear. This study was undertaken to investigate the role of oxidative damage in ofloxacin (one typical quinolones)-induced arthropathy. Chondrocytes from juvenile rabbit joints were incubated with ofloxacin at concentrations of 0, 5, 10, 20, 40 and 80 ug/mL, respectively. The extent of oxidative damage was assessed by measuring the reactive oxygen species level, activities of antioxidant enzymes, and oxidative damage to some macromolecules. It was observed that ofloxacin induced a concentration-dependent increase in intracellular reactive oxygen species production, which may be an early mediator of ofloxacin cytotoxicity. Similarly, ofloxacin resulted in a significant lipid peroxidation, revealed by a concentration-dependent increase in the level of thiobarbituric acid reactive substances. At the same time, ofloxacin induced DNA damage in a concentration-dependent manner for 24 hr measured by comet assay, which may be a cause for overproduction of reactive oxygen species. Furthermore, antioxidant enzyme activities, such as glutathione peroxidase (GPx), catalase and superoxide dismutase (SOD), were rapidly decreased after treatment with ofloxacin. In addition, SOD decline and reactive oxygen species production were strongly inhibited, and the loss in cell viability was partly abated by additional glutathione (GSH), N-acetylcysteine (NAC) and dithiothreitol (DTT). In conclusion, these results clearly demonstrated that ofloxacin could induce oxidative stress, lipid peroxidation and DNA oxidative damage to chondrocytes. Ofloxacin is a quinolone antimicrobial agent. The mechanism of action of ofloxacin and o

Source: PubChem (NCBI) ยท compound 4583

Product Manufacturer Status Country
ORNILOX
ORNIDAZOLE 500MG AND OFLOXACIN 200MG
Micro Labs Registered Kenya
ORNIMED-O TABLET
OFLOXACIN USP 200MG AND ORNIDAZOLE 500MG
Zuvan Registered Kenya
OWIN D EYE DROPS
OFLOXACIN USP 0.3% W/V DEXAMETHASONE SODIUM PHOSPHATE USP EQ. TO DEXAMETHASONE 0.1% W/V BENZALKONIUM CHLORIDE N.F (AS PRESERVATIVE) 0.01% W/V STERILE AQUEOUS BASE Q.S.
Europa Healthcare Registered Kenya
POLYMIC TABLET
200MG +500MG
Zawadi Healthcare Registered Kenya
PROTOZOL
OFLOXACIN 200MG AND ORNIDAZOLE 500MG PER TABLET
Wessex Pharmaceuticals Registered Kenya
SARAOFLO-OZ
OFLOXACIN BP 200MG AND ORNIDAZOLE 500MG
Krishna Chemists Registered Kenya
SARAOFLO-OZ
OFLOXACIN BP 200MG AND ORNIDAZOLE 500MG
Krishna Chemists Registered Kenya
SUNFLOX-400
400MG
Zawadi Healthcare Registered Kenya
TARIVID 200MG TABLET
200MG
Sanofi Aventis Registered Kenya
TERBIBACT MIXI
OFLOXACIN 0.75% W/W, ORNIDAZOLE 2.0% W/W, TERBINAFINE HYDROCHLORIDE 1.0% W/W & CLOBETASOL PROPIONATE 0.05% W/W
Galaxy Pharmaceutical Registered Kenya
TOFLOX TZ
OFLOXACIN USP 200MG + TINIDAZOLE BP 600MG / TABLET
Medox Pharmaceuticals Registered Kenya
UROFLAV-D TABLETS
200 MG AND 200 MG
Psm Pharmaceuticals Registered Kenya
XAFLO-OD TABLETS
EACH FILM COATED TABLET CONTAINS: OFLOXACIN BP 200 MG AND ORNIDAZOLE 500 MG
Dinlas Pharma - Kenya
XIN-O
200MG AND 500MG RESPECTIVELY
Crown Healthcare Registered Kenya
XIN-O
200MG AND 500MG RESPECTIVELY
Crown Healthcare Registered Kenya
Z-OFLOX OZ
200MG + 500MG
Zawadi Healthcare Registered Kenya
ZOFEX
2MG/ML
Reddys Pharma Registered Kenya
ZOFLOX TABLETS
OFLOXACIN BP 200 MG AND ORNIDAZOLE 500 MG
Dolopharma Registered Kenya
12